Please assess the completion status of the following clinical trial:

Trial Title: Study FFR116364, a Placebo-controlled Study of GW685698X in Paediatric Subjects With Perennial Allergic Rhinitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed Consent~* 6 to \<15 years of age, male or eligible female (females of childbearing potential must commit to consistent and correct use of an acceptable method of birth control), outpatient~* Diagnosis of perennial allergic rhinitis: A positive test response to house dust and/or dust mites on serum antigen-specific IgE antibody test at Visit 1. One year or more clinical history of perennial allergic rhinitis. A positive test result on nasal eosinophil count at Visit 1/1A.~* Either subject's parent/guardian who signed ICF or subject is able to complete assessments on the patient diary through the study.~* ALT \< 2xULN; alkaline phosphatase and bilirubin \<= 1.5xULN~* Average of 3TNSS is \>= 4.0 in the last consecutive 4 days prior to Visit 2.~* Completion of the patient diary on \>= 3 days of the last consecutive 4 days prior to Visit 2~Exclusion Criteria:~* Has a seasonal pollen as an allergen~* A nose disorder that could affect the assessment of the study medication or eye or nose surgery (within 3 months prior to Visit 1)~* Bacterial or viral infection of upper respiratory tract or eye~* Concurrent disease/abnormalities: Clinically significant uncontrolled disease~* Known hypersensitivity to corticosteroids or any excipients in the investigational product~* Has recent participation in a study and/or exposure to an investigational study drug within 3 months prior to Visit 1~* Use of the following medication and/or its combination drug within the specified time:~Anti-IgE (Within 6 months prior to Visit 1), Immunosuppressive medications or Systemic corticosteroids (Within 8 weeks prior to Visit 1), Topical corticosteroids (Within 4 weeks prior to Visit 1), Immunotherapy or nonspecific allassotherapy which was initiated, discontinued or changed its dose within 4 weeks prior to Visit 1~* Affiliation with Investigator's Site: Relative or employee~* History of alcohol or drug abuse, children in care or in the opinion of the investigator (sub-investigator), inappropriate to be enrolled in the study.~* Average of 3TNSS is \>= 8.0 in the last consecutive 4 days prior to Visit 2.~* Bacterial or viral infection of upper respiratory tract or eye during the screening period.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- GW685698X (Type: EXPERIMENTAL): GW685698X 55mcg/day
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).